NSAIDs and COVID-19: A New Challenging Area

Hananeh Baradaran ¹ , Hadi Hamishehkar ², Haleh Rezaee ² *

Cited by CrossRef: 5

1- Ghanavati M, Tadayon F, Basiryanmahabadi A, Torabi Fard N, Smiley E. Design of new sensing layer based on ZnO/NiO/Fe3O4/MWCNTs nanocomposite for simultaneous electrochemical determination of Naproxen and Sumatriptan. Journal of Pharmaceutical and Biomedical Analysis. 2023;223:115091 [Crossref]

2- Kiani P, Scholey A, Dahl T, McMann L, Iversen J, Verster J. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. Viruses. 2021;13(4):558 [Crossref]

3- Pourkarim F, Pourtaghi‐Anvarian S, Rezaee H. Molnupiravir: A new candidate for COVID‐19 treatment. Pharmacology Res & Perspec. 2022;10(1) [Crossref]

4- Mohamed S, El Bakri Y, Abdul D, Ahmad S, Albayati M, Lai C, Mague J, Tolba M. Synthesis, crystal structure, and a molecular modeling approach to identify effective antiviral hydrazide derivative against the main protease of SARS-CoV-2. Journal of Molecular Structure. 2022;1265:133391 [Crossref]

5- Esalatmanesh K, Azadbakht J, Hajialilo M, Soroush M, Esalatmanesh R, Soleimani Z, Khabbazi A. Clinical course, chest computed tomography severity score and outcome of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases. The Egyptian Rheumatologist. 2022;44(3):245 [Crossref]

Submit Your Paper Editorial Board Instructions for Authors Instructions for Reviewers Contact Us Editorial Policies Peer Review Archive

Indexing & Abstracting:

Follow us on LinkedIn
Follow us on Twitter

Director-in-Charge:
Prof. Khosro Adibkia

Editor-in-Chief:
Prof. Ali Shayanfar

Follower of ICMJE